FineMark National Bank & Trust lowered its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 103,998 shares of the company’s stock after selling 2,210 shares during the quarter. FineMark National Bank & Trust’s holdings in Johnson & Johnson were worth $16,120,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently made changes to their positions in the company. GW&K Investment Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $35,000. Dark Forest Capital Management LP increased its position in Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares during the period. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $42,000. Kepos Capital LP acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $45,000. Finally, VitalStone Financial LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $52,000. Institutional investors and hedge funds own 67.57% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. Credit Suisse Group increased their price target on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Stifel Nicolaus increased their target price on Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Morgan Stanley reiterated an “equal weight” rating and issued a $187.00 target price on shares of Johnson & Johnson in a report on Friday, July 21st. Finally, Citigroup assumed coverage on Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $171.80.
Johnson & Johnson Trading Down 0.3 %
Shares of JNJ opened at $172.92 on Wednesday. The business has a 50-day moving average of $165.50 and a 200 day moving average of $161.20. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The firm has a market cap of $449.41 billion, a P/E ratio of 35.00, a price-to-earnings-growth ratio of 2.92 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.59 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is presently 96.36%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders sold 47,163 shares of company stock valued at $7,928,856 in the last quarter. 0.20% of the stock is currently owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Are Penny Stocks a Good Fit for Your Portfolio?
- On Holding Slips Into A More Comfortable Price PointÂ
- What is a Mid Cap Stock? How to Invest
- 3 Growing Cannabis Stocks Ready To Bloom
- How to Invest in Energy
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
